"GlycoVision results featured at ESMO 2024: read the interview here to learn how InterVenn is powering new prognostic and predictive biomarkers!
Back to blog list
November 10, 2021
30 Blood-based glycoprotein signatures in advanced non-small-cell lung carcinoma (NSCLC) receiving first-line immune checkpoint blockade

Get in touch